Arcturus Therapeutics (ARCT) Competitors $16.02 -2.32 (-12.65%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends ARCT vs. RVNC, STOK, MRSN, NGM, STTK, NAMS, NRIX, HRMY, WVE, and SYREShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Revance Therapeutics (RVNC), Stoke Therapeutics (STOK), Mersana Therapeutics (MRSN), NGM Biopharmaceuticals (NGM), Shattuck Labs (STTK), NewAmsterdam Pharma (NAMS), Nurix Therapeutics (NRIX), Harmony Biosciences (HRMY), Wave Life Sciences (WVE), and Spyre Therapeutics (SYRE). These companies are all part of the "medical" sector. Arcturus Therapeutics vs. Revance Therapeutics Stoke Therapeutics Mersana Therapeutics NGM Biopharmaceuticals Shattuck Labs NewAmsterdam Pharma Nurix Therapeutics Harmony Biosciences Wave Life Sciences Spyre Therapeutics Revance Therapeutics (NASDAQ:RVNC) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Which has better earnings and valuation, RVNC or ARCT? Arcturus Therapeutics has lower revenue, but higher earnings than Revance Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevance Therapeutics$234.04M1.87-$323.99M-$1.93-2.16Arcturus Therapeutics$169.93M2.55-$29.73M-$2.22-7.22 Does the MarketBeat Community prefer RVNC or ARCT? Arcturus Therapeutics received 35 more outperform votes than Revance Therapeutics when rated by MarketBeat users. Likewise, 65.86% of users gave Arcturus Therapeutics an outperform vote while only 62.07% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformRevance TherapeuticsOutperform Votes40162.07% Underperform Votes24537.93% Arcturus TherapeuticsOutperform Votes43665.86% Underperform Votes22634.14% Does the media refer more to RVNC or ARCT? In the previous week, Arcturus Therapeutics had 5 more articles in the media than Revance Therapeutics. MarketBeat recorded 13 mentions for Arcturus Therapeutics and 8 mentions for Revance Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.74 beat Revance Therapeutics' score of -0.09 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revance Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of RVNC or ARCT? 97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by company insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, RVNC or ARCT? Revance Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Is RVNC or ARCT more profitable? Arcturus Therapeutics has a net margin of -36.39% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Revance Therapeutics-74.67% N/A -37.22% Arcturus Therapeutics -36.39%-22.39%-14.81% Do analysts prefer RVNC or ARCT? Revance Therapeutics presently has a consensus price target of $9.66, suggesting a potential upside of 131.59%. Arcturus Therapeutics has a consensus price target of $71.40, suggesting a potential upside of 345.69%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Revance Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revance Therapeutics 0 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.11Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryArcturus Therapeutics beats Revance Therapeutics on 14 of the 19 factors compared between the two stocks. Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$433.93M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-7.224.4062.6013.00Price / Sales2.55377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book1.669.636.455.92Net Income-$29.73M$154.43M$119.73M$225.73M7 Day Performance-18.37%-9.46%-5.13%-1.34%1 Month Performance-22.23%-7.27%-2.71%1.15%1 Year Performance-35.89%28.13%31.08%24.02% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.514 of 5 stars$16.02-12.6%$71.40+345.7%-27.8%$433.93M$169.93M-7.22180High Trading VolumeRVNCRevance Therapeutics3.8657 of 5 stars$3.79+2.4%N/A-39.7%$397.27M$234.04M-1.96597STOKStoke Therapeutics3.9035 of 5 stars$14.06+1.3%N/A+188.5%$744.76M$8.78M-6.70100News CoverageMRSNMersana Therapeutics4.3148 of 5 stars$2.52-1.9%N/A+43.5%$309.15M$36.85M-2.90150Analyst ForecastAnalyst RevisionNews CoverageNGMNGM Biopharmaceuticals3.5585 of 5 stars$1.54-1.3%N/A+155.2%$128.53M$4.42M-0.90138STTKShattuck Labs3.0521 of 5 stars$1.18flatN/A-40.3%$56.32M$4.12M-0.64100Analyst ForecastAnalyst RevisionNews CoverageNAMSNewAmsterdam Pharma3.0191 of 5 stars$24.55+1.8%N/A+150.5%$2.21B$14.09M0.0057Short Interest ↑News CoverageNRIXNurix Therapeutics2.6769 of 5 stars$29.24+6.9%N/A+277.6%$2.07B$76.99M-10.05300Positive NewsHRMYHarmony Biosciences4.8494 of 5 stars$36.26+0.5%N/A+28.5%$2.07B$582.02M17.18200Short Interest ↓WVEWave Life Sciences4.8718 of 5 stars$16.51+0.4%N/A+149.0%$2.06B$113.31M-28.96240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageSYRESpyre Therapeutics2.4611 of 5 stars$39.64+0.2%N/AN/A$2.02B$890,000.00-2.57100Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Revance Therapeutics Alternatives Stoke Therapeutics Alternatives Mersana Therapeutics Alternatives NGM Biopharmaceuticals Alternatives Shattuck Labs Alternatives NewAmsterdam Pharma Alternatives Nurix Therapeutics Alternatives Harmony Biosciences Alternatives Wave Life Sciences Alternatives Spyre Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
